Materials and methods for respiratory disease control in canines

An isolated virus that comprises one or more polynucleotides wherein said one or more polynucleotides encode a canine influenza virus protein selected from the group consisting of HA, NA, NP, MA, PB1, PB2, PA, and NS, or a functional or immunogenic fragment thereof.

A method for detection of an influenza virus that is capable of infecting a canid animal, said method comprising obtaining a sample containing nucleic acid from an animal, and contacting said nucleic acid sample with a forward and reverse oligonucleotide primer that binds specifically to a polynucleotide or gene sequence of said virus under conditions sufficient for generation of an amplification product if the nucleic acid contains a sequence to which said primers bind;

• and detecting said amplification product.

A method for protecting a canine from an influenza virus infection, wherein the method comprises administering to the canine a therapeutically effective amount of a vaccine comprising:

• at least one equine influenza virus antigen, and
• at least one pharmaceutically acceptable excipient.

A method for protecting a canine from an H3 influenza virus infection, wherein the method comprises administering to the canine a therapeutically effective amount of a vaccine comprising:

• at least one H3 influenza virus antigen and/or at least one H7 influenza virus antigen, and
• at least one pharmaceutically acceptable excipient.

A method for protecting a canine from respiratory lesions caused by canine influenza virus, wherein the method comprises administering to the canine a therapeutically effective amount of a vaccine comprising:

• at least one equine influenza virus antigen, and
• at least one pharmaceutically acceptable excipient.

A method for protecting a canine from respiratory lesions caused by canine influenza virus, wherein the method comprises administering to the canine a therapeutically effective amount of a vaccine comprising:

• at least one H3 influenza virus antigen and/or at least one H7 influenza virus antigen, and
• at least one pharmaceutically acceptable excipient.

A method for protecting a canine from having canine influenza virus in nasal or oral secretion caused by canine influenza virus infection, wherein the method comprises administering to the canine a therapeutically effective amount of a vaccine comprising:

• at least one equine influenza virus antigen, and
• at least one pharmaceutically acceptable excipient.

A method for protecting a canine from having canine influenza virus in nasal or oral secretion caused by canine influenza virus infection, wherein the method comprises administering to the canine a therapeutically effective amount of a vaccine comprising:

• at least one H3 influenza virus antigen and/or at least one H7 influenza virus antigen, and
• at least one pharmaceutically acceptable excipient.

A canine influenza vaccine, wherein the vaccine comprises:

• a therapeutically effective amount of at least one H3 influenza virus antigen and/or at least one H7 influenza virus antigen, and
• at least one pharmaceutically acceptable excipient.

A canine influenza vaccine, wherein the vaccine comprises:

• a therapeutically effective amount of an equine influenza virus antigen, and
• at least one pharmaceutically acceptable excipient.